br weakness on diagnosis of a parotid gland malignant process

weakness on diagnosis of a parotid gland malignant process. Eur Arch Otorhinolaryngol 2012;269:1177–82.
[11] Preis M, Soudry E, Bachar G, Shufel H, Feinmesser R, Shpitzer T. Predicting facial nerve invasion by parotid gland carcinoma and outcome of facial reanimation. Eur Arch Otorhinolaryngol 2010;267:107. [12] Swendseid B, Li S, Thuener J, Rezaee R, Lavertu P, Fowler N, et al. Incidence of facial nerve sacrifice in parotidectomy for primary and metastatic malignancies. Oral Oncol 2017;73:43–7.
[15] Casler JD, Conley JJ. Surgical management of adenoid cystic carcinoma in the parotid gland. Otolaryngol—Head Neck Surg 1992;106:332–8. [16] Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, et al. Head and neck cancers. J National Compr Cancer Network: JNCCN 2011;9:596–650. [17] House JW, Brackmann DE. Facial nerve grading system. Laryngoscope 1985;93:146–7. [18] Jang JY, Choi N, Ko Y-H, Chung MK, Son Y-I, Baek C-H, et al. Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1–2 N0 high-grade salivary gland cancer. BMC cancer 2018;18:672. [19] Tweedie DJ, Jacob A. Surgery of the parotid gland: U 46619 of techniques, no-
menclature and a revised classification system. Clin Otolaryngol: Off J ENT-UK; Off J Netherlands Soc Oto-Rhino-Laryngol Cervico-Facial Surg 2009;34:303–8. [20] Spector JG, Lee P, Peterein J, Roufa D. Facial nerve regeneration through auto-logous nerve grafts: a clinical and experimental study. Laryngoscope 1991;101:537–54.
[21] Eaton DA, Hirsch BE, Mansour OI. Recovery of facial nerve function after repair or grafting: our experience with 24 patients. Am J Otolaryngol 2007;28:37–41. [22] Mehta RP. Surgical treatment of facial paralysis. Clin Exp Otorhinolaryngol 2009;2:1–5. [23] Dulguerov P, Marchal F, Lehmann W. Postparotidectomy facial nerve paralysis: possible etiologic factors and results with routine facial nerve monitoring. Laryngoscope 1999;109:754–62.
[26] Chu J, Zhou Z, Hong G, Guan J, Li S, Rao L, et al. High-resolution MRI of the intraparotid facial nerve based on a microsurface coil and a 3D reversed fast ima-ging with steady-state precession DWI sequence at 3T. AJNR Am J Neuroradiol 2013;34:1643–8.
Contents lists available at ScienceDirect
Am J Otolaryngol
journal homepage: www.elsevier.com/locate/amjoto
Clinical practice patterns in laryngeal cancer and introduction of CT lung T screening☆,☆☆,☆☆☆
Krzysztof Piersialaa,b, Lee M. Aksta, Alexander T. Hillela, Simon R. Besta,
a Department of Otolaryngology – Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, United States of America
b Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute, Stockholm, Sweden
Keywords:
Lung cancer screening
Laryngeal cancer
Head and neck cancer
Lung cancer
Objectives: After the publication of large clinical trials, in January 2014 The U.S. Preventive Services Task Force (USPSTF) recommended annual lung cancer screening with low-dose CT in a well-defined group of high-risk smokers. A significant proportion of patients with laryngeal cancer (LC) meet the introduced criteria, and we hypothesized chlamydia clinical practice would change as a result of these evidence-based guidelines.
Methods: Retrospective chart review of patients diagnosed with LC and treated at Johns Hopkins Hospital who met USPSTF criteria for annual chest screening and were followed for at least 3 consecutive years in the years surrounding the introduction of screening guidelines (January 2010 to December 2017) was performed to identify those who had recommended screening CT chest.